Lifang Pharmaceutical has received approval from China's National Medical Products Administration for its Azilsartan Medoxomil Potassium tablets, indicated for treating adult primary hypertension. This marks a significant step for the company in the pharmaceutical sector. The approval covers both 40mg and 80mg dosages of the medication. AI
RANK_REASON Company received drug registration certificate from regulatory body. [lever_c_demoted from research: ic=1 ai=0.1]
- Azilsartan Medoxomil Potassium tablets
- Lifang Pharmaceutical
- National Medical Products Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
